The pericardium is the layer that surrounds the heart. The pericardium has two layers that work to lubricate the heart, protect it, and prevent it from filling up with too much blood. When this layer ...

Kiniksa Pharmaceuticals (KNSA) just delivered its third quarter earnings, highlighting an impressive jump in ARCALYST revenue and a shift to positive net income. The company also updated its guidance, ...

ARCALYST(R) (rilonacept) Meets Primary and All Secondary Endpoints in Phase 3 Trial of Prevention of Gout Flares in Patients Initiating Allopurinol Therapy Regeneron plans to file by mid-2011 for ...

Regeneron's ARCALYST® (rilonacept) Reduced Incidence of Gout Flares by 81 Percent in a Phase 2 Study in Gout Patients Initiating Urate-Lowering Therapy Proportion of patients experiencing gout flares ...

I used to hold Kiniksa (KNSA) a few years ago, and also regularly covered it. I note from my past writings that my regular opinion about KNSA was that it was a solid but boring stock. That the stock ...

CEO Sanj Patel highlighted that Kiniksa achieved $137.8 million in net product revenue for ARCALYST during Q1 2025, marking a 75% increase year-over-year. This success was attributed to robust ...

Tarrytown, NY (August 11, 2008) – Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the publication of the results of three studies which supported the U.S. Food and Drug Administration ...

Regeneron announced that its Phase 3 study of Arcalyst (rilonacept injection) met its primary and secondary endpoints for the prevention of gout attacks. This trial, known as PRE-SURGE 1 (PREventative ...

HAMILTON, Bermuda, June 08, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate immunological ...

Regeneron announced results from its second Phase 3 study of Arcalyst (rilonacept) for the treatment of gout patients initiating allopurinol therapy. This trial, known as the global PRE-SURGE 2 ...